Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | CASP9 | P55211 | 2/20 | 0.59 |
| ▸ | CASP6 | P55212 | 2/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384302 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24213871 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL14646635 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29043505 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL30376490 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL8353502 | 0.90 | CASP3 (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23268995 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23269036 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313593-A1 | DIPEPTIDE DERIVATIVE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | BEIJING CONTINENT PHARMACEUTICALS CO., LTD (CN) | 2025-10-09 | — | — | US | disclosed |
| EP-4520344-A1 | DIPEPTIDE DERIVATIVE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Continent Pharmaceuticals Co., Ltd. (CN) | 2025-03-12 | — | — | EP | disclosed |
| CN-117045634-A | Dipeptide derivative composition and preparation method and application thereof | 北京康蒂尼药业股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP7 10/4885CASP9 12/4885 |
| US-20250313593-A1 | DIPEPTIDE DERIVATIVE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | VIP, NGLY1, PELP1 | CASP3 3008/4885CASP7 1146/4885CASP9 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.